2-phenyl-4-chloroimidazo<1,2-a>quinoxaline | 158225-38-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-phenyl-4-chloroimidazo<1,2-a>quinoxaline
• 英文别名: 4-Chloro-2-phenylimidazo[1,2-a]quinoxaline
• CAS: 158225-38-8
• 化学式: C₁₆H₁₀ClN₃
• 分子量: 279.728
• InChiKey: CYQAPXXOPJHTHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-phenyl-4-chloroimidazo<1,2-a>quinoxaline 在 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以83%的产率得到2-Phenyl-imidazo-[1,2-a]-quinoxalin-4(5H)-one
  参考文献：
  名称：

  Catarzi; Cecchi; Colotta, Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2846 - 2850

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-3-氯喹喔啉 以55%的产率得到
  参考文献：
  名称：

  Catarzi Damela, Cecchi Lucia, Colotta Vittoria, Melani Fabrizio, Filacchi+, J. Med. Chem, 37 (1994) N 18, S 2846- 2850

  摘要：

  DOI：

文献信息

• IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS
  申请人：Deleuze-Masquefa Carine

  公开号：US20100249142A1

  公开（公告）日：2010-09-30

  Imidazo[1,2-a]quinoxaline compounds for the treatment of cancers as well as pharmaceutical compositions that include these compounds and their uses in therapy. The compound of general formula (I):

  咪唑并[1,2-a]喹噁啉化合物用于治疗癌症，以及包括这些化合物的药物组合物和它们在疗法中的用途。通式(I)的化合物：
• [EN] FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY<br/>[FR] COMPOSÉS TRICYCLIQUES CONDENSÉS POSSÉDANT UNE ACTIVITÉ ANTAGONISTE DES RÉCEPTEURS A2A DE L'ADÉNOSINE
  申请人：SCHERING CORP

  公开号：WO2011060207A1

  公开（公告）日：2011-05-19

  The present invention relates to certain certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the "Fused Tricyclic Compounds"), wherein M, Q, U, W, X, Y, Z, R1, R2, and R3, and rings C and D are as herein described. The present invention also provides compositions comprising at least one Fused Tricyclic Compound, and use of such compounds in the treatment of central nervous system diseases or disorders such as Parkinson's disease.

  本发明涉及公式(I)中的某些融合三环杂环烷基环化合物（在此处也称为“融合三环化合物”），其中M、Q、U、W、X、Y、Z、R1、R2和R3以及环C和环D如所述。本发明还提供包含至少一种融合三环化合物的组合物，并利用这些化合物治疗中枢神经系统疾病或障碍，如帕金森病。
• Synthesis of some tricyclic heteroaromatic systems and their A1 and A2a adenosine binding activity
  作者：V Colotta、L Cecchi、D Catarzi、G Filacchioni、C Martini、P Tacchi、A Lucacchini

  DOI：10.1016/0223-5234(96)88218-3

  日期：1995.1

  The syntheses, A(1) and A(2a) adenosine receptor affinities and structure-activity relationships of some 2-aryl-1,2,4-triazolo[1,5-a]quinoxalines, 2-arylimidazo[1,2-a]quinoxalines, 1-arylimidazo[1,5-a]quinoxalines are reported and compared with that of a previously reported 2-phenylpyrazolo[1,5-a]quinoxaline. The results show that some triazoloquinoxalines are potent and specific A(1) adenosine receptor ligands and that the replacement of either nitrogen at position 1 or 3 of the triazoloquinoxaline moiety with a CH brought about a decrease in affinity at both adenosine receptors.
• FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
  申请人：Harris Joel M.

  公开号：US20120232086A1

  公开（公告）日：2012-09-13

  The present invention relates to certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the “Fused Tricyclic Compounds”), wherein M, Q, U, W, X, Y, Z, R 1 , R 2 , and R 3 , and rings C and D are as herein described. The present invention also provides compositions comprising at least one Fused Tricyclic Compound, and use of such compounds in the treatment of central nervous system diseases or disorders such as Parkinson's disease.
• US8378098B2
  申请人：——

  公开号：US8378098B2

  公开（公告）日：2013-02-19